Results 61 to 70 of about 2,555,654 (307)

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq, Abdul Qayyum, Mubashar Naqvi, Tariq Gill, Muhammad Khalid, Ammara Tahir, Abid Jamil, Ahmad Khalid, Mahwish Khan, Muhammad Ferhan, Ijaz Shah, Abid Taj, Weng Qin, Mudassar Iqbal, Muhammad Abbad, Aamer Aleem, Tanveer Akhtar, Zafar Iqbal, Najeeb ur-Rehman, Shahid Baig   +19 more
core  

Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells

Tumor Biology, 2017
Chronic myeloid leukemia is characterized by the presence of the reciprocal translocation t(9;22) and the BCR/ABL oncogene. The BCR/ABL oncogene activates multiple signaling pathways and involves the dysregulation of oncogenes during the progression of ...
Jia-Hua Zhang, Yan-Li He, Rui Zhu, Wen Du, Jun-Hua Xiao   +4 more
doaj   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Chronic myeloid leukemia in Asia

International Journal of Hematology, 2008
Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM, Glivec) has supplanted busulphan, hydroxyurea and interferon-alpha as first-line treatment.
Jootar, S, Kim, DW, O'Neil, WM, Caguioa, PB, Kweon, IY, Hsu, SC, Chuah, C, Saikia, TK, Au, WY, Wang, J   +9 more
openaire   +4 more sources

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Case report: Co-existing chronic myeloid leukemia and chronic myelomonocytic leukemia–A clinically important but challenging scenario

Leukemia Research Reports, 2023
Chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML) are two common myeloid neoplasms with overlapping morphologic features. We report a patient initially diagnosed with CML and treated with Tyrosine kinase inhibitor (TKI) but who ...
Jinming Song, Lynn Moscinski, Ling Zhang, Hailing Zhang   +3 more
doaj   +1 more source

Bone Organoids Across the Development‐to‐Remodeling Continuum: From Tissue Formation to Functional Competence and Translation

Advanced Healthcare Materials, EarlyView.
Mineralization alone does not establish a mature bone organoid. This Review integrates biological foundations, materials design, adaptive remodeling, and translational validation through the development‐to‐remodeling continuum (DRC). By separating biological functions from the evidence supporting them, the framework exposes critical gaps in current ...
Xijie Tang, Haijia Xu, Xiangzhong Liu, Yi Yang, Zhanghua Li   +4 more
wiley   +1 more source

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. [PDF]

, 2011
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells.
Carsten Bokemeyer, Balabanov, S., Moll, J., Tessa L. Holyoake, Edgar Jost, Braig, Melanie, Stefan Balabanov, Moll, Jürgen, Rohe, Imke, Gontarewicz, A., Gunhild Keller, von Amsberg, Gunhild, Braig, M., Holyoake, Tessa L., Jost, E., Rohe, I., Jost, Edgar, Bosotti, Roberta, Tim H Brümmendorf, Bosotti, R., Balabanov, Stefan, Barett, Christine, Artur Gontarewicz, Holyoake, T.L., Laura Raddrizzani, Brümmendorf, T.H., Gontarewicz, Artur, Roberta Bosotti, Barett, C., Raddrizzani, Laura, Melanie Braig, Raddrizzani, L., Bokemeyer, C., Jürgen Moll, Tessa L Holyoake, Keller, G., Tim H. Brümmendorf, Bokemeyer, Carsten, Brümmendorf, Tim Henrik, Imke Rohe, Christine Barett   +40 more
core   +2 more sources

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia [PDF]

Frontiers in Oncology, 2015
The suppression of the immune system creates a permissive environment for development and progression of cancer. One population of immunosuppressive cells that have become the focus of intense study is myeloid derived suppressor cells (MDSCs), immature myeloid cells able to induce immune-escape, angiogenesis, and tumor progression.
Cesarina eGiallongo, Nunziatina eParrinello, Maria Violetta Brundo, Salvatore Antonino Raccuia, Salvatore Antonino Raccuia, Michelino eDi Rosa, Piera eLa Cava, Tibullo eDaniele   +7 more
openaire   +6 more sources

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source